UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR
REGISTRATION UNDER SECTION 12(b) OF THE
SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-11960
AstraZeneca PLC
New York Stock Exchange
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Telephone: +44 20 3749 5000
(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)
American Depositary Shares, each representing one half of an Ordinary Share of 25¢ each
Ordinary Shares of 25¢ each
2.375% Notes due 2020
2.375% Notes due 2022
Floating Rate Notes due 2022
3.500% Notes due 2023
7.000% Notes due 2023
Floating Rate Notes due 2023
3.375% Notes due 2025
0.700% Notes due 2026
3.125% Notes due 2027
4.000% Notes due 2029
1.375% Notes due 2030
6.450% Notes due 2037
4.000% Notes due 2042
4.375% Notes due 2045
4.375% Notes due 2048
2.125% Notes due 2050
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
o 17 CFR 240.12d2-2(a)(1)
o 17 CFR 240.12d2-2(a)(2)
o 17 CFR 240.12d2-2(a)(3)
o 17 CFR 240.12d2-2(a)(4)
o Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.(1)
x Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements of the Securities Exchange Act of 1934,AstraZeneca PLC (Name of Issuer or Exchange) certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
|
September 24, 2020
|
|
By
|
/s/ Adrian Kemp
|
|
Company Secretary
|
|
Date
|
|
|
Name
|
|
Title
|
(1) Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.